文献速递乳腺癌

高危早期乳腺癌保乳术后瘤床同步与序贯加量的III期试验

Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.
PubMed 文献 · J Clin Oncol · 2026-05-11

PURPOSE: For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration.…

要点

  • 同步加量组同侧乳腺复发非劣效于序贯加量组。
  • 两组不良事件、美容效果和生存无差异。
  • 同步加量缩短总治疗时间。

核心结论

  • 全乳放疗期间同步加量相比序贯加量,同侧乳腺复发非劣效,且不增加毒性或恶化美容效果,并缩短总治疗时间。

研究设计与样本

  • NRG/RTOG 1005是一项III期随机试验,纳入2354例保乳术后高危同侧乳腺复发患者,随机分配至序贯加量组(n=1118)或同步加量组(n=1137),2255例可分析。

主要发现

  • 中位随访7.3年,共56例同侧乳腺复发事件。
  • 序贯加量组5年和7年同侧乳腺复发率分别为2.1%和2.2%,同步加量组分别为1.9%和2.6%。
  • 两组不良事件、美容效果或生存无差异。

关键数值与推荐

  • 序贯加量方案:全乳放疗50 Gy/25次或42.7 Gy/16次后,序贯加量12 Gy/6次或14 Gy/7次。
  • 同步加量方案:全乳放疗40 Gy/15次期间同步加量8 Gy/15次(每日0.53 Gy)。
  • 非劣效性界值定义为90%CI风险比上限2.12。

临床怎么用

  • 对于保乳术后高危早期乳腺癌患者,可考虑全乳放疗期间同步加量以缩短治疗时间,且不增加毒性或恶化美容效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS: NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS: Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION: Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vicini FA, Winter K, Freedman GM, et al. Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial. J Clin Oncol. 2026. PMID: 42114027. doi:10.1200/JCO-25-02465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。